Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31074609 | 0.80 | DGAT1 (0.34) | NPC1DGAT1 | |
| SCHEMBL31074772 | 0.80 | NPC1 (0.30) | NPC1 | |
| SCHEMBL31074692 | 0.79 | ALOX5AP (0.33) | NPC1DGAT1 | |
| SCHEMBL24753784 | 0.79 | DGAT1 (0.32) | NPC1DGAT1 | |
| SCHEMBL31074481 | 0.79 | NPC1 (0.32) | NPC1DGAT1 | |
| SCHEMBL21544284 | 0.79 | NPC1 (0.32) | NPC1DGAT1 | |
| SCHEMBL31074682 | 0.77 | ALDH1A1 (0.33) | — | |
| SCHEMBL31074467 | 0.75 | NPC1 (0.31) | NPC1 | |
| SCHEMBL31074649 | 0.75 | DGAT1 (0.32) | NPC1DGAT1 | |
| SCHEMBL31074516 | 0.75 | NPC1 (0.31) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665734-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-20240360137-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| WO-2024171094-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | NOVARTIS AG (CH) | 2024-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360137-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | CDK2, CDK1, CCNK | NPC1 2825/4885DGAT1 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.